Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

Bibliographic Details
Main Authors: Redondo, Andrés, Martínez, Virginia, Zamora, Pilar, Castelo, Beatriz, Pinto, Alvaro, Cruz, Patricia, Higuera, Oliver, Mendiola, Marta, Hardisson, David, Espinosa, Enrique
Format: Online
Language:English
Published: Dove Medical Press 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251573/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251573/

Similar Items